SUPN — Recent News Coverage

All news mentioning SUPN in ESEN's AI-graded feed

News stories with SUPN as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on SUPN. See /coverage/SUPN for the 30-day aggregate.

7 articles Updated: 2026-08-27 07:23 UTC Filter: Ticker: $SUPN
FINANCE.YAHOO.COM · 2026-08-04 NEUTRAL NEUTRAL CORR0.42

Supernus and Indivior merge to create scaled, CNS-focused entity

$SUPN $INVA
◈ ESEN AI
Supernus Pharmaceuticals and Indivior are combining operations to establish a scaled pharmaceutical entity with concentrated expertise in central nervous system (CNS) disorders and opioid use disorder (OUD) treatments. …
SEEKINGALPHA.COM · 2026-08-03 HIGH BULLISH CORR0.72

Supernus Pharmaceuticals, Inc. (SUPN) M&A Call Transcript

$SUPN
◈ ESEN AI
Supernus Pharmaceuticals (SUPN) disclosed M&A activity through an official earnings call transcript, signaling corporate action that typically triggers equity volatility and investor repositioning. M&A announcements rep…
SEEKINGALPHA · 2026-08-03 NEUTRAL BULLISH CORR0.42

Supernus, Indivior stock jumps after all-stock deal to merge

$SUPN $INDV
◈ ESEN AI
SUPN and INDV announced an all-stock merger, triggering immediate positive price action in both equities. All-stock deals typically signal management confidence in valuation multiples while avoiding cash drain, though e…
MANILATIMES.NET · 2026-08-03 HIGH BULLISH CORR0.72

Supernus Announces Second Quarter 2026 Financial Results

$SUPN $INDV
◈ ESEN AI
Supernus Pharmaceuticals delivered a 32% revenue beat in Q2 2026, with core growth products surging 52% year-over-year to $175.7M. This acceleration reflects strong commercial execution across the CNS portfolio, particu…
MANILATIMES.NET · 2026-08-03 HIGH BULLISH CORR0.72

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

$SUPN $INDV
◈ ESEN AI
Supernus Pharmaceuticals (SUPN) and Indivior announced a merger creating a combined CNS biopharmaceutical entity with approximately $2.2 billion in annual revenues. This transaction represents a significant consolidatio…
GLOBALNEWSWIRE · 2026-08-03 HIGH BULLISH CORR0.72

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

$SUPN $INDV
◈ ESEN AI
The all-stock merger between Supernus Pharmaceuticals (SUPN) and Indivior Pharmaceuticals (INDV) represents a significant consolidation event in the CNS biopharmaceutical sector. This combination creates a scaled divers…
MANILATIMES.NET · 2026-06-17 LOW BULLISH CORR0.42

Supernus Expands Partnership With MERGE as AI-Powered Agency of Record

$SUPN
◈ ESEN AI
Supernus Pharmaceuticals (SUPN) announced an expanded partnership with MERGE, designating the agency as its artificial intelligence-powered agency of record. This strategic broadening of an existing relationship reflect…
EXPLORE OTHER FILTERS